Author(s): Muss HB, Blessing JA, DuBeshter B
Abstract Share this page
Abstract Twenty-one evaluable patients with recurrent or metastatic endometrial carcinoma were treated with 1,500 micrograms/m2 of echinomycin every 3 weeks. All patients had received prior chemotherapy. There was one complete response (5\%), 95\% confidence interval for response is 0.9-22.7\%. The major toxicity was nausea and vomiting which was moderate to severe in 42\% of patients. Myelosuppression was minimal. Echinomycin, in this dose and schedule, displays minimal activity in patients with advanced endometrial carcinoma who have had prior chemotherapy.
This article was published in Am J Clin Oncol
and referenced in Pediatrics & Therapeutics